There were numerous articles in October 2018 that covered a wide range of topical issues. Here are five of the best stories you might have missed… (Click the headline to finish reading the story)
Recently medicinal cannabis has been at the forefront of media attention in the U.K., and in July 2018 the U.K. home secretary announced that specialist doctors can legally prescribe cannabis-based products in the event of an exceptional clinical need.
This decision by the Home Office will place cannabidiol products into Schedule 2 of the Misuse of Drugs Regulations 2001, meaning it can be possessed lawfully by anyone who is given a prescription. Could this radical change in policy potentially cause the U.K. to further relax its regulations, especially if medicinal cannabis proves efficacious and safe in other clinical trials?
Mental health is something millions of people face on a daily basis; however, how many of those actually seek help? Stigmas attached to mental health mean those suffering feel unable to speak out, fearful of how others will react. World Mental Health Day gives support and strength to those struggling, reminding them help is available. The date is 10/10 – but is your mental health?
Mental health is among the leading causes of ill-health and disability worldwide, affecting 450 million individuals worldwide. In 2017, the U.K. recorded its lowest rates of suicide since records began in 1981, showing the importance of awareness schemes and spotlight events, such as Mental Health Day. However, there is still so much more that can be done.
With the Medical Device Regulation (MDR) starting make its presence felt within the industry, device companies, large and small, have been making process adjustments, ensuring they comply with the new laws.
The MDR’s implementation, while steady, has beget a sea of change that could have lasting implications on how device trials are run and approved. CTA’s Jisong Seo sits down with Dorota Johansson, who’s the Clinical Director of Bactiguard.
In this Industry Viewpoint, Johansson discusses the latest challenges affecting the medical device space, and offers insights on how to overcome them.
The way clinical trials are being conducted needs to change. If the patient’s perspectives, expectations, fears and doubts are not being addressed, then clinical trials can never fully become successful. All stakeholders involved in the clinical trial must align all decisions with the patient’s wants, needs and preferences.
Information about the trial, the process, the people involved all need to be channeled through the patient. If we want patients to be committed to the clinical trials, then we need to commit to engaging and empowering the patients before, during and after the clinical trial.
Imagine a future with happy patients, high recruitment and low dropout rates. The typical clinical trial of the future incorporates patient perspectives. The focus is centered on the patient and less on the trial.
As the saying goes, “a picture is worth a thousand words.” However, when it comes to medical imaging, a picture can be worth two, or even sometimes three thousand words. In fact, it is difficult to even imagine modern health care without any imaging whatsoever. Aside from non-invasively diagnosing a patient, imaging plays a key role in determining treatment efficacy. Over the years, several types of imaging have been developed, each one as unique as the other.
All of the major imaging modalities on the market today have their advantages. Nuclear imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT) offer great functional information in terms of drug quantification and assessing its biodistribution. Computed tomography (CT), also known as a CAT scan, remains the quickest modality and the go-to imaging choice of many emergency situations.
Be sure to check out CTA this week as we’re shining a spotlight on Outsourcing! Stay tuned!!